Capacity Expansion Rottendorf Pharma is actively expanding manufacturing capacity with the new Rottendorf Campus in Oelde, Germany, signaling increased production capabilities and potential for higher contract volumes with global clients seeking scalable solid dosage form manufacturing.

Global Footprint Recent office relocations and campus expansion across Europe and the U.S. suggest strong geographic coverage and proximity to key markets, enabling more localized CDMO support for multinational clients and faster time-to-market for global projects.

TPO TT With Total Process Ownership and Total Technological Mastering, the company positions itself as an integrated extension of clients’ operations, appealing to brands seeking seamless development, scale-up, and reliable supply of solid oral dosage forms without competing in the market.

Digital Edge Adoption of advanced tech stack including ValGenesis VLMS, cloud platforms (AWS, Azure), analytics (Power BI), and AI tools indicates strong digital capabilities for quality, compliance, and process optimization—selling point for clients prioritizing modern, compliant CDMO ecosystems.

Stability & Scale With 95 years in the industry, a diverse product portfolio of over 600 originator and generic drugs, and a revenue range of 50–100 million, Rottendorf offers established reliability and scale for both large biologics-adjacent programs and smaller, diverse solid-dose projects.